May 2026
Includes: exposing a new weakness in prostate tumors, delaying disease progression, prostate cancer overdiagnosis rises sharply with age,
Co-Designing Better Pathways for Prostate Health
Jonathon Gabbai, from the Provincial Pathways Unit joins us to discuss how his provincial health team is helping support better, more consistent care in Alberta for those affected with prostate cancer.
Meals on Wheels
Christine Hentschel, Manager at Calgary Meals on Wheels gives a presentation on the organization, how they’ve grown to over 1.2 million deliveries a year, the services they offer, and the importance of nutrition
Introduction to PARP-Inhibitors and their role in Cancer Treatment
Dr. Geoffrey Gotto, Urologic Oncologist at the Southern Alberta Institute of Urology, joins us again to explain PARP inhibitors and their importance in modern treatment of cancer cells.
February 2026
Includes: Spotlighting the Top 10 FDA Oncology Approvals in 2025, CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction,
January 2026
Includes: Prostate cancer cells thrive in bone tissue, Top 10 Urology Times prostate cancer articles of 2025, Reversing treatment resistance in prostate cancer,
December 2025
Includes: Focused ultrasound offers safe and effective prostate cancer treatment, Neuromodulation therapy for erectile dysfunction after radical prostatectomy,
A History of Cancer Clinical Trials in Canada
Dr. Fedir Razumenko from the University of Calgary joins us for a look at the progression of cancer treatment in Canada, comparing stats from the 1920s to today and how today’s treatments were forged by brave and competitive voices throughout the country.
November 2025
Includes: Drug combo cuts risk of death in advanced prostate cancer by 40%, targeting enzymes to weaken cancer cells could supercharge treatment,
Introduction to PARP Inhibitors
Dr. Tarek Bismar from the Prostate Cancer Centre joins us again to talk about PARP inhibitors and their role in cancer treatment. He shows their activity in cancer cells, synergy with other cancer therapies, and how people respond depending on their cancer type.